Clinical trial
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's…
NCT00412321 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00412321 |
|---|---|
| Title | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease |
| Official title | A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia |
| Intervention type | Drug |
| Interventions | CNTO 328 |
| Enrollment | 67 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Dec 18, 2006 |
| Last update posted | Jul 1, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: